For health care professionals in EUROPE excepted those practicing in France as the following pages are intended to all International health care professionals and are not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Other health care professionals should select their country in the top right corner of the website.
Please note that the following pages are exclusively reserved for health care professionals in countries with applicable health authority product registrations. To the extent this site contains information, reference guides and databases intended for use by licensed medical professionals, such materials are not intended to offer professional medical advice. Prior to use, please consult device labeling for prescriptive information and operating instructions.
This Website is protected by the laws on copyright and by the relevant international conventions. It is strictly forbidden to make copies, whether partial or total and on whichever media without prior approval.
The WATCHMAN LAA Closure Technology is intended to prevent thrombus embolization from the left atrial appendage and reduce the risk of life-threatening bleeding events in patients with non-valvular atrial fibrillation who are eligible for anticoagulation therapy or who have a contraindication to anticoagulation therapy.1
The ESC guidelines recommend to assess the stroke and bleeding risks in the decision-making process for thromboprophylaxis in patients with non-valvular AF by using respectively the CHA2DS2-VASc and HAS-BLED scores.
“Decision-making for thromboprophylaxis needs to balance the risk of stroke against the risk of major bleeding, especially ICH, which is the most feared complication of anticoagulation therapy and confers a high risk of death and disability” (ESC guidelines 2012)
CHA2DS2-VASc is a risk assessment system developed by Lip et. Al., which refines the older CHADS2 score by including additional stroke risk factors and putting greater emphasis on age as a risk factor.2,3
Lip GY et al, Chest 2010; 137(2): 263-72
Camm AJ et al, Eur Heart J 2010; 31, 2369-2429
HAS-BLED score was developed as a practical risk score to estimate the 1-year risk for major bleeding in patients with AF.4
Pisters R, et al. Chest 2010; 138: 1093-100
European Heart Journal 2012 - doi:10.1093/eurheartj/ehs253
The Boston Scientific Stroke-Bleed Risks Calculator will help you easily balance the risk of stroke against the risk of bleeding prior to decide the best treatment option for your AF patients; and consider the LAAC therapy for your AF patients who are at high risk of stroke & bleeding.
See real-life clinical cases of patients successfully implanted with the WATCHMAN LAAC device.
Explore the medical profiles of patient eligible and not eligible for the WATCHMAN LAAC therapy.
The WATCHMAN™ LAAC Device offers patients with atrial fibrillation a life-changing treatment option which can free them from the burden of long-term warfarin therapy.
The WATCHMAN Device has been implanted in thousands of patients around the world. Here you can watch the testimonials of individuals as they describe their personal experiences, both before and after treatment. Click on a video to hear AF patients discuss how the WATCHMAN Device has changed their lives:
These stories reflect the experience of individuals with a WATCHMAN Left Atrial Appendage Closure Device. Boston Scientific invited these people to share their stories candidly. Please bear in mind that the experiences are specific to these particular individuals. Not everyone who receives left atrial appendage closure therapy will receive the same results as the individuals in these stories.
The WATCHMAN™ LAAC Device is intended to prevent thrombus embolization from the left atrial appendage and reduce the risk of life-threatening bleeding events in patients with non-valvular atrial fibrillation who are eligible for anticoagulation therapy or who have a contraindication to anticoagulation therapy.